Misplaced Pages

Tilomisole

Names
Preferred IUPAC name thiazolo benzimidazol-2-yl]acetic acid
Identifiers
CAS Number	58433-11-7
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL2104737
ChemSpider	38987
KEGG	D06148
PubChem CID	42747
UNII	651G60U372
CompTox Dashboard (EPA)	DTXSID40207137
InChI InChI=1S/C17H11ClN2O2S/c18-11-7-5-10(6-8-11)16-14(9-15(21)22)23-17-19-12-3-1-2-4-13(12)20(16)17/h1-8H,9H2,(H,21,22)
SMILES Clc4ccc(c1c(sc2nc3ccccc3n12)CC(=O)O)cc4
Properties
Chemical formula	C17H11ClN2O2S
Molar mass	342.80 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references

Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.

References

1. Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolobenzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. doi:10.3109/08923978009026408. PMID 6970786.
2. Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Immunology
• Experimental cancer drugs
• Imidazothiazoles
• Antineoplastic and immunomodulating drug stubs